Literature DB >> 28691560

Bispecific Antibody Therapy in Hemophilia.

David Lillicrap1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28691560     DOI： 10.1056/NEJMe1707802

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

Review 1.  Emicizumab-kxwh: First Global Approval.

Authors:  Lesley J Scott; Esther S Kim
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

2.  Annual Bleeding Rates: Pitfalls of Clinical Trial Outcomes in Hemophilia Patients.

Authors:  Christine Keipert; Mirco Müller-Olling; Franca Gauly; Cornelia Arras-Reiter; Anneliese Hilger
Journal:  Clin Transl Sci       Date:  2020-05-30       Impact factor: 4.689

3.  Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries.

Authors:  Pallavi Bhatta; Kevin D Whale; Amy K Sawtell; Clare L Thompson; Stephen E Rapecki; David A Cook; Breda M Twomey; Milena Mennecozzi; Laura E Starkie; Emily M C Barry; Shirley J Peters; Ahmad M Kamal; Helene M Finney
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.